Vorinostat - Unravel Biosciences
Alternative Names: RVL-001Latest Information Update: 20 Feb 2025
At a glance
- Originator Unravel Biosciences
- Class Antineoplastics; Hydroxamic acids; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Pitt-Hopkins syndrome; Rett syndrome
Most Recent Events
- 20 Feb 2025 Phase-0 trials in Pitt-Hopkins syndrome in USA (unspecified route) prior to February 2025 (Unravel Biosciences Pipeline, February 2025)
- 20 Feb 2025 Phase-0 trials in Rett syndrome in USA (unspecified route) prior to February 2025 (Unravel Biosciences Pipeline, February 2025)
- 24 Oct 2024 Unravel Biosciences plans a proof-of-concept trial for Rett syndrome in Rett syndrome (RTT) and Pitt Hopkins syndrome (PTHS) in USA, in early 2025